Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises
18.11.2025 10:00:00 CET | Business Wire | Press release
Series A led by Creandum, with Elaia and Speedinvest, will accelerate the product development of GetVocal’s AI customer experience platform
GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces.
Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in black-box autonomous systems – by building trustworthy, transparent, and governed AI agents that accelerate the customer experience (CX) market’s transition from “humans assisted by AI” to “AI powered by humans.”
Unlike other agents on the market, GetVocal’s large language models (LLMs) follow a strict business logic and are only deployed where AI works best – ensuring that humans are in the loop when crucial decisions happen. GetVocal’s CX platform acts as a single governing layer, orchestrating real-time collaboration between human and AI agents in a controlled environment, monitoring every conversation and alerting when human intervention is needed. Designed with the complexities of Europe in mind, the platform reliably supports the gradual shift of responsibilities to AI while maintaining complete transparency, auditability and compliance with the EU AI Act.
“Research by the MIT Media Lab shows that 95 percent of companies fail to get financial value from AI pilots because they lack the skills, processes, and governance to effectively integrate AI. Our customers are proudly in the five percent,” said GetVocal CEO and Co-founder Roy Moussa. “We look forward to restoring confidence in AI agents and offering Europe’s thriving enterprises a pragmatic solution to embed them in their customer experience operations. This funding will directly support the continued development of our hybrid workforce management capabilities and enable us to grow our international team and expand our commercial reach across Europe.”
Major brands such as Vodafone, Glovo, and Movistar already trust GetVocal to simplify and enhance complex customer service interactions, achieving tangible impact at scale, while a pilot is in progress at Deutsche Telekom. For example, Glovo grew its agent fleet from one to 80 AI agents in less than 12 weeks. Bruno Machado, Senior Operations Manager at Glovo, said, “Deploying GetVocal has transformed how we serve our community. From reactivating users to streamlining management, the results speak for themselves: a five-fold increase in uptime and a 35 percent increase in deflection, in just weeks. GetVocal is accelerating our growth and ensuring that we remain a platform users can always count on.”
Compared to existing enterprise solutions, GetVocal’s AI agents drive 31 percent fewer live escalations, 45 percent more self-service resolutions, and achieve a 70 percent deflection rate within three months of launch. This means customers can double efficiency gains while maintaining high satisfaction scores.
GetVocal’s AI agents are fully auditable, adhere to Europe’s strictest data sovereignty requirements and can be deployed on a self-hosted basis, making them ideal for enterprises seeking to prove compliance with the EU AI Act and similar emerging regulations.
“Black-box AI erodes accountability, and legacy contact-centre software locks organisations into rigid workflows unsuitable for day-to-day operations. GetVocal has built a winning platform that enables true automation while providing a level of control over agent behaviour that supports scaling without abandoning responsibility,” explained Hanel Baveja, Partner at Creandum, who will be joining GetVocal’s board.
About GetVocal
GetVocal is the conversational AI platform built for hybrid human-AI workforces. Enterprises rely on GetVocal to build, govern, and optimise hybrid agent fleets - monitoring customer support conversations in real time, intervening instantly, and safely shifting from human to AI service as automation skills evolve. With transparency and control at its core, GetVocal helps organisations modernise customer operations responsibly - without compromising on experience or trust.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118820169/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom